Mid-Atlantic Biotherapeutics is a Doylestown, PA–based biotech developing therapies for neurological disorders, aging-related diseases, and cancer using its IMT504 immunotherapy platform. The company is led by CEO and Founder Dr. David Horn and focuses on conditions such as Alzheimer’s and Parkinson’s as well as other severe neurological disorders. Its proprietary molecule IMT504 harnesses the body’s immune response and has shown safety and efficacy in animal models and in humans, with an immunostimulatory profile demonstrated in humans and multiple primate models. The IMT504 platform also creates partnering and collaboration opportunities in infectious-disease applications. MABT is the first company to receive Orphan Drug Designation for late-stage rabies, which could enable a more rapid regulatory pathway and extended market exclusivity. The company intends to use the funds to support continued clinical development, research initiatives, and regulatory efforts. Mid-Atlantic BioTherapeutics (MABT) is a US clinical-stage biopharmaceutical company founded in 2011 focused on immunotherapy approaches for infectious diseases, with a flagship program targeting rabies. Its lead product is described as ready for adaptive, late-stage clinical trials and has received Orphan Drug Designation. The company expects to qualify for a Priority Review Voucher (PRV) upon successful clinical testing of the lead product. MABT says proceeds from financings will be used to advance the lead adaptive late-stage trials, accelerate the path to market approval, and push other programs to meaningful inflection points. MABT is planning a pre-IPO round and aims for a NASDAQ listing within the next 24 months. A recent financing agreement provides contingent capital to support these development and commercialization objectives.

Total raised

$55M

Funding rounds

2

Latest round

Equity

Latest activity

Aug 2025